Clinical Trials on Pancreatic Adenocarcinoma in United Kingdom

Total 6898 results

Lisa Bax
Roche Pharma AG; Genentech, Inc.

Terminated

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) (HIPPoS)

Pancreatic Ductal Adenocarcinoma

United Kingdom
NHS Greater Glasgow and Clyde

Recruiting

Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) (AIR-PANC)

Pancreatic Ductal Adenocarcinoma

United Kingdom
Cambridge University Hospitals NHS Foundation Trust

Completed

Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United Kingdom
Imperial College London
The Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS Foundation... and other collaborators

Recruiting

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR)

Pancreatic Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

United Kingdom
Barts & The London NHS Trust
King's College London; Cambridge University Hospitals NHS Foundation Trust; Medical... and other collaborators

Completed

Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)

Pancreatic Adenocarcinoma

United Kingdom
The Christie NHS Foundation Trust
Manchester University NHS Foundation Trust

Completed

PDAC Peripheral and Portal Vein Sampling

Pancreatic Adenocarcinoma

United Kingdom
University of Oxford
National Institute for Health Research, United Kingdom; Imunon

Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours (PanDox)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectable

United Kingdom
Royal Marsden NHS Foundation Trust

Unknown

A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers (PaC-MAn)

Pancreatic Adenocarcinoma

United Kingdom
University Hospital Birmingham NHS Foundation Trust

Recruiting

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma

United Kingdom
CCTU- Cancer Theme
Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK; Celgene

Terminated

Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) (PRICKLE)

Pancreatic Adenocarcinoma

United Kingdom
Royal Cornwall Hospitals Trust
Biocartis

Completed

KEBI-Cyto Study - Use of the Biocartis Idylla

Pancreatic Adenocarcinoma | Lung Cancer

United Kingdom
Queen's University, Belfast
Belfast Health and Social Care Trust; Pancreatic Cancer UK

Completed

PRECISE: Pancreatic Cancer and Exercise

Pancreas Adenocarcinoma

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
The Gurdon Institute; Ann McLaren Laboratory of Regenerative Medicine

Unknown

In Vitro Models of Liver and Pancreatic Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma | Pancreatic Neoplasm

United Kingdom
Queen Mary University of London
Imperial College London; University College, London; University of Liverpool; Pancreatic...

Recruiting

Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (UroPanc)

Pancreatic Ductal Adenocarcinoma

United Kingdom
The Christie NHS Foundation Trust
Pancreatic Cancer UK

Completed

Pancreatic Cancer Dietary Assessment Study (PanDA)

Pancreas Adenocarcinoma | Pancreatic Neoplasm | Malignant Neoplasm of Pancreas | Well-Differentiated Neuroendocrine Carcinoma

United Kingdom
Roswell Park Cancer Institute

Not yet recruiting

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
The Clatterbridge Cancer Centre NHS Foundation...
Cancer Research UK; University of Liverpool

Suspended

Acelarin First Line Randomised Pancreatic Study (ACELARATE)

Pancreatic Neoplasms | Pancreatic Acinar Carcinoma

United Kingdom
CCTU- Cancer Theme
Celgene

Completed

Scheduling Nab-paclitaxel With Gemcitabine (SIEGE)

Pancreatic Adenocarcinoma Metastatic

United Kingdom
AstraZeneca

Completed

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States, United Kingdom
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
HonorHealth Research Institute

Active, not recruiting

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Untreated Resectable Pancreatic Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
ERYtech Pharma

Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)

Pancreatic Adenocarcinoma

United States, United Kingdom, France
Memorial Sloan Kettering Cancer Center

Recruiting

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Georgetown University
ERYtech Pharma

Active, not recruiting

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditions

United States
University of Medicine and Pharmacy Craiova
Odense University Hospital; University of Bergen; University of Witten/Herdecke; Newcastle-upon-Tyne Hospitals NHS Trust and other collaborators

Completed

Endoscopic Ultrasound Elastography in Pancreatic Masses (EUS-EG)

Pancreatic Adenocarcinoma | Chronic Pancreatitis

United Kingdom, Denmark, Italy, France, Germany, Belgium, Netherlands, Norway, Romania, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Lexicon Pharmaceuticals

Active, not recruiting

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Recurrent Pancreatic Adenocarcinoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Recruiting

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Acinar Cell Carcinoma | Ampulla of Vater Adenocarcinoma | Periampullary Adenocarcinoma | Duodenal Adenocarcinoma | Pancreatic Intraductal Papillary Mucinous Neoplasm

United States
Kimberly Perez, MD
Novartis

Terminated

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic Adenocarcinoma

United States
Colin D. Weekes, M.D., PhD
Actuate Therapeutics Inc.; Lustgarten Foundation

Recruiting

FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic

United States
Adenocyte, LLC

Enrolling by invitation

The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma | Pancreatic Intraepithelial Neoplasia

United States
Dana-Farber Cancer Institute

Recruiting

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma

United States
University of Utah
National Cancer Institute (NCI)

Active, not recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
M.D. Anderson Cancer Center

Active, not recruiting

Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Advanced Pancreatic Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Brandon Huffman
Stand Up To Cancer; Lustgarten Foundation; K-Group, Beta, Inc., a wholly owned...

Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Mayo Clinic

Recruiting

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma

United States
University of Virginia

Active, not recruiting

BATs Treatment for Pancreatic Cancer, Phase Ib/II

Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
Weill Medical College of Cornell University
Cambridge University Hospitals NHS Foundation Trust

Terminated

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Pancreas Cancer

United States, United Kingdom
University of California, Davis
Bristol-Myers Squibb; National Cancer Institute (NCI); Dynavax Technologies Corporation

Completed

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Refractory Pancreatic Adenocarcinoma

United States
Hitendra Patel
Cancer Research UK; Stand Up To Cancer; Lustgarten Foundation; HonorHealth Research... and other collaborators

Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma Resectable | Pancreatic Metastasis

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
The Cooper Health System

Terminated

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
Jun Gong, MD
Emmaus Medical, Inc.

Active, not recruiting

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
HonorHealth Research Institute
Mayo Clinic; University of California, San Diego; Cancer Research UK; Stand Up... and other collaborators

Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD)

Adenocarcinoma | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreas Metastases

United States

Clinical Trials on Pancreatic Adenocarcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations